{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T14:54:21Z","timestamp":1785596061797,"version":"3.56.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010857","name":"Jiangxi Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["20204BCJ23024"],"award-info":[{"award-number":["20204BCJ23024"]}],"id":[{"id":"10.13039\/501100010857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81860035"],"award-info":[{"award-number":["81860035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["J230022"],"award-info":[{"award-number":["J230022"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41397-024-00359-6","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T05:09:55Z","timestamp":1732252195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study"],"prefix":"10.1038","volume":"24","author":[{"given":"Yue","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fancong","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoquan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhentao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"key":"359_CR1","doi-asserted-by":"publisher","first-page":"354","DOI":"10.2174\/157489211796957775","volume":"6","author":"R Masetti","year":"2011","unstructured":"Masetti R, Kleinschmidt K, Biagi C, Pession A. Emerging targeted therapies for pediatric acute myeloid leukemia. Recent Pat Anticancer Drug Discov. 2011;6:354\u201366.","journal-title":"Recent Pat Anticancer Drug Discov."},{"key":"359_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387.","journal-title":"Blood Rev"},{"key":"359_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/1574892817666220429105338","volume":"18","author":"RG Mih\u0103il\u0103","year":"2023","unstructured":"Mih\u0103il\u0103 RG. Venetoclax in acute myeloid leukemia. Recent Pat Anticancer Drug Discov. 2023;18:11\u201328.","journal-title":"Recent Pat Anticancer Drug Discov."},{"key":"359_CR4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","volume":"21","author":"DA Pollyea","year":"2023","unstructured":"Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, et al. Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21:503\u201313.","journal-title":"J Natl Compr Canc Netw"},{"key":"359_CR5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ajh.26083","volume":"96","author":"JL Kaufman","year":"2021","unstructured":"Kaufman JL, Gasparetto C, Schjesvold FH, Moreau P, Touzeau C, Facon T, et al. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma. Am J Hematol. 2021;96:418\u201327.","journal-title":"Am J Hematol"},{"key":"359_CR6","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1182\/blood.2020006578","volume":"137","author":"F Morschhauser","year":"2021","unstructured":"Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Ill\u00e9s \u00c1, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137:600\u20139.","journal-title":"Blood"},{"key":"359_CR7","first-page":"2628","volume":"136","author":"PL Zinzani","year":"2020","unstructured":"Zinzani PL, Flinn IW, Yuen SLS, Topp MS, Rusconi C, Fleury I, et al. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed\/refractory follicular lymphoma. Blood. 2020;136:2628\u201337.","journal-title":"Blood"},{"key":"359_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100805","volume":"61","author":"K \u0160imoni\u010dov\u00e1","year":"2022","unstructured":"\u0160imoni\u010dov\u00e1 K, Janotka \u013d, Kavcov\u00e1 H, Sulov\u00e1 Z, Breier A, Messingerova L. Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia. Drug Resist Updat. 2022;61:100805.","journal-title":"Drug Resist Updat."},{"key":"359_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101120","volume":"76","author":"T Li","year":"2024","unstructured":"Li T, Gao R, Xu K, Pan P, Chen C, Wang D, et al. BCL7A inhibits the progression and drug-resistance in acute myeloid leukemia. Drug Resist Updat. 2024;76:101120.","journal-title":"Drug Resist Updat."},{"key":"359_CR10","doi-asserted-by":"crossref","unstructured":"C\u00e2mara AB, Brand\u00e3o IA. The Non-Hodgkin Lymphoma treatment and side effects: a systematic review and meta-analysis. Recent Pat Anticancer Drug Discov. 2024;19:93\u2013120.","DOI":"10.2174\/1574892818666230117151757"},{"key":"359_CR11","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/hon.2646","volume":"37","author":"S Agarwal","year":"2019","unstructured":"Agarwal S, Gopalakrishnan S, Mensing S, Potluri J, Hayslip J, Kirschbrown W, et al. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: an exposure-response analysis. Hematol Oncol. 2019;37:464\u201373.","journal-title":"Hematol Oncol"},{"key":"359_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/00007691-200404000-00019","volume":"26","author":"L Wojnowski","year":"2004","unstructured":"Wojnowski L. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit. 2004;26:192\u20139.","journal-title":"Ther Drug Monit"},{"key":"359_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1517\/17425255.2016.1163337","volume":"12","author":"N Hohmann","year":"2016","unstructured":"Hohmann N, Haefeli WE, Mikus G. CYP3A activity: towards dose adaptation to the individual. Expert Opin Drug Metab Toxicol. 2016;12:479\u201397.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"359_CR14","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00228-019-02704-2","volume":"75","author":"SL Groenland","year":"2019","unstructured":"Groenland SL, Mathijssen RHJ, Beijnen JH, Huitema ADR, Steeghs N. Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine. Eur J Clin Pharmacol. 2019;75:1309\u201318.","journal-title":"Eur J Clin Pharmacol"},{"key":"359_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01865-y","volume":"39","author":"M Kobayashi","year":"2022","unstructured":"Kobayashi M, Yasu T, Suzaki K, Kosugi N. Utility of therapeutic drug monitoring of venetoclax in acute myeloid leukemia. Med Oncol. 2022;39:259.","journal-title":"Med Oncol"},{"key":"359_CR16","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","volume":"76","author":"ED Deeks","year":"2016","unstructured":"Deeks ED. Venetoclax: first global approval. Drugs. 2016;76:979\u201387.","journal-title":"Drugs"},{"key":"359_CR17","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1111\/ajt.14232","volume":"17","author":"T Vanhove","year":"2017","unstructured":"Vanhove T, Bouwsma H, Hilbrands L, Swen JJ, Spriet I, Annaert P, et al. Determinants of the magnitude of interaction between tacrolimus and voriconazole\/posaconazole in solid organ recipients. Am J Transplant. 2017;17:2372\u201380.","journal-title":"Am J Transplant"},{"key":"359_CR18","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1002\/jcph.937","volume":"57","author":"CJ Lucas","year":"2017","unstructured":"Lucas CJ, Martin JH. Pharmacokinetic-guided dosing of new oral cancer agents. J Clin Pharmacol. 2017;57:S78\u2013S98.","journal-title":"J Clin Pharmacol"},{"key":"359_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40262-014-0137-2","volume":"53","author":"H Yu","year":"2014","unstructured":"Yu H, Steeghs N, Nijenhuis CM, Schellens JH, Beijnen JH, Huitema AD. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet. 2014;53:305\u201325.","journal-title":"Clin Pharmacokinet"},{"key":"359_CR20","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/jcph.741","volume":"56","author":"AH Salem","year":"2016","unstructured":"Salem AH, Agarwal SK, Dunbar M, Nuthalapati S, Chien D, Freise KJ, et al. Effect of low- and high-fat meals on the pharmacokinetics of venetoclax, a selective first-in-class BCL-2 inhibitor. J Clin Pharmacol. 2016;56:1355\u201361.","journal-title":"J Clin Pharmacol"},{"key":"359_CR21","first-page":"542","volume":"43","author":"X Chen","year":"2022","unstructured":"Chen X, Liu ZY, Zhang RL, Zhai WH, Ma QL, Pang AM, et al. [Efficacy and safety of Venetoclax in the treatment of 25 patients with recurrent hematologic malignancies after an allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2022;43:542\u20139. Chinese","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"359_CR22","first-page":"812","volume":"35","author":"KX Li","year":"2022","unstructured":"Li KX, Zhao WW, Liu Y, Gao XY, Zhou FH, Chen QP, et al. [The value of venetoclax blood concentration monitoring in the treatment of acute myeloid leukemia and the eficacy and safety of combined azacytidine in the treatment of acute myeloid leukemia]. J Clin Hematol. 2022;35:812\u20136.","journal-title":"J Clin Hematol"},{"key":"359_CR23","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1200\/JCO.2017.72.6745","volume":"35","author":"JP Leonard","year":"2017","unstructured":"Leonard JP, Martin P, Roboz GJ. Practical implications of the 2016 revision of the World Health Organization classification of lymphoid and myeloid neoplasms and acute leukemia. J Clin Oncol. 2017;35:2708\u201315.","journal-title":"J Clin Oncol"},{"key":"359_CR24","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"359_CR25","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3390\/molecules27051607","volume":"27","author":"X Yang","year":"2022","unstructured":"Yang X, Mei C, He X, He L, Lu X, Tong H, et al. Quantification of Venetoclax for therapeutic drug monitoring in Chinese acute myeloid leukemia patients by a validated UPLC-MS\/MS method. Molecules. 2022;27:1607.","journal-title":"Molecules"},{"key":"359_CR26","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1089\/gtmb.2017.0088","volume":"21","author":"F Liu","year":"2017","unstructured":"Liu F, Ou YM, Yu AR, Xiong L, Xin HW. Long-term influence of CYP3A5, CYP3A4, ABCB1, and NR1I2 polymorphisms on tacrolimus concentration in chinese renal transplant recipients. Genet Test Mol Biomarkers. 2017;21:663\u201373.","journal-title":"Genet Test Mol Biomarkers"},{"key":"359_CR27","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/jcpt.13407","volume":"46","author":"Y Jing","year":"2021","unstructured":"Jing Y, Kong Y, Hou X, Liu H, Fu Q, Jiao Z, et al. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients. J Clin Pharm Ther. 2021;46:1117\u201328.","journal-title":"J Clin Pharm Ther"},{"key":"359_CR28","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","volume":"39","author":"SK Agarwal","year":"2017","unstructured":"Agarwal SK, DiNardo CD, Potluri J, Dunbar M, Kantarjian HM, Humerickhouse RA, et al. Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther. 2017;39:359\u201367.","journal-title":"Clin Ther"},{"key":"359_CR29","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1124\/dmd.116.071613","volume":"45","author":"H Liu","year":"2017","unstructured":"Liu H, Michmerhuizen MJ, Lao Y, Wan K, Salem AH, Sawicki J, et al. Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites. Drug Metab Dispos. 2017;45:294\u2013305.","journal-title":"Drug Metab Dispos"},{"key":"359_CR30","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3390\/pharmaceutics15061680","volume":"15","author":"S De Gregori","year":"2023","unstructured":"De Gregori S, Gelli E, Capone M, Gambini G, Roncoroni E, Rossi M, et al. Pharmacokinetics of venetoclax co-administered with posaconazole in patients with acute myeloid leukemia. Pharmaceutics. 2023;15:1680.","journal-title":"Pharmaceutics."},{"key":"359_CR31","doi-asserted-by":"crossref","unstructured":"Kobayashi T, Sato H, Miura M, Fukushi Y, Kuroki W, Ito F, et al. Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia. Cancer Chemother Pharmacol. 2024;94:285\u201396.","DOI":"10.1007\/s00280-024-04673-5"},{"key":"359_CR32","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/cpdd.395","volume":"7","author":"TT Cheung","year":"2018","unstructured":"Cheung TT, Salem AH, Menon RM, Munasinghe WP, Bueno OF, Agarwal SK. Pharmacokinetics of the BCL-2 inhibitor venetoclax in healthy Chinese subjects. Clin Pharmacol Drug Dev. 2018;7:435\u201340.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"359_CR33","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/hon.2964","volume":"40","author":"D Brackman","year":"2022","unstructured":"Brackman D, Eckert D, Menon R, Salem AH, Potluri J, Smith BD, et al. Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-na\u00efve acute myeloid leukemia who are ineligible for intensive chemotherapy. Hematol Oncol. 2022;40:269\u201379.","journal-title":"Hematol Oncol"},{"key":"359_CR34","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/chromsci\/bmac027","volume":"61","author":"T Yasu","year":"2023","unstructured":"Yasu T, Gando Y, Nomura Y, Kosugi N, Kobayashi M. Determination of venetoclax concentration in plasma using high-performance liquid chromatography. J Chromatogr Sci. 2023;61:480\u20133.","journal-title":"J Chromatogr Sci"},{"key":"359_CR35","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1097\/CAD.0000000000000522","volume":"28","author":"AH Salem","year":"2017","unstructured":"Salem AH, Dunbar M, Agarwal SK. Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia. Anticancer Drugs. 2017;28:911\u20134.","journal-title":"Anticancer Drugs"},{"key":"359_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2023.115279","volume":"227","author":"P Gao","year":"2023","unstructured":"Gao P, Zhang W, Fang X, Leng B, Zhang Y, Liu X, et al. Simultaneous quantification of venetoclax and voriconazole in human plasma by UHPLC-MS\/MS and its application in acute myeloid leukemia patients. J Pharm Biomed Anal. 2023;227:115279.","journal-title":"J Pharm Biomed Anal"},{"key":"359_CR37","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2217\/pgs-2019-0189","volume":"21","author":"JN Patel","year":"2020","unstructured":"Patel JN, Hamadeh IS. Pharmacogenetics and tacrolimus administration in stem cell transplantation. Pharmacogenomics. 2020;21:419\u201326.","journal-title":"Pharmacogenomics."},{"key":"359_CR38","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3390\/pharmaceutics14030559","volume":"14","author":"\u00c1 Pinto-Merino","year":"2022","unstructured":"Pinto-Merino \u00c1, Labrador J, Zubiaur P, Alcaraz R, Herrero MJ, Montesinos P, et al. Role of pharmacogenetics in the treatment of acute myeloid leukemia: systematic review and future perspectives. Pharmaceutics. 2022;14:559.","journal-title":"Pharmaceutics."},{"key":"359_CR39","unstructured":"Dean L. Voriconazole Therapy and CYP2C19 Genotype. 2019 Dec 27. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical genetics summaries. Bethesda (MD): National Center for Biotechnology Information (US); 2012."}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41397-024-00359-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-024-00359-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-024-00359-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T06:07:19Z","timestamp":1734588439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-024-00359-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["359"],"URL":"https:\/\/doi.org\/10.1038\/s41397-024-00359-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4565192\/v1","asserted-by":"object"}]},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]},"assertion":[{"value":"11 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods in this study were carried out in accordance with relevant guidelines and regulations. The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University (IIT 2024190), and all ethical standards and requirements were strictly adhered to. All participants involved in this study signed an informed consent form, and ensured that the privacy and personal information of the participants were fully protected throughout the research process.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"37"}}